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July 2013 limited availability and low spatial resolution impair the use of positron emission tomography in routine clinical practice. To overcome these limitations, molecular MRI of inflammation using ultrasmall particles of iron oxide has been described in preclinical 8 and clinical studies. 9 Nevertheless, this approach has significant limits, which preclude its use in the acute and subacute phases of stroke, including an uncompressible time between injection and imaging (>24 hours to allow plasmatic clearance of the iron particles), a passive extravasation through altered blood-brain barriers (which could lead to false-positive findings in both acute and subacute phases), and a low sensitivity to detect the early steps of inflammation. 8, 9 We recently developed an original contrast agent targeting the vascular cell adhesion molecule-1 (VCAM-1), which displays all the required characteristics of an ideal imaging agent, thus allowing a rapid and sensitive assessment of the early stages of the inflammatory reaction. 10 In the present study, we investigated the efficiency of these microsized particles of iron oxide targeting VCAM-1 (MPIOs-αVCAM-1) to monitor cerebrovascular inflammation and evaluate the response to anti-inflammatory treatments after ischemic and hemorrhagic strokes.
Materials and Methods
The Materials and Methods section is available as an online supplement.
Results

Inflammatory Response Differs Between Permanent and Transient Middle Cerebral Artery Occlusion as Assessed by MPIOs-αVCAM-1 Imaging
Using MPIOs-αVCAM-1-enhanced imaging, we first aimed to compare temporal and spatial evolutions of cerebrovascular inflammation after permanent middle cerebral artery occlusion (pMCAo; by electrocoagulation) and transient MCAo (tMCAo; by microinjection of thrombin leading to intra-arterial thrombus formation followed by a spontaneous reperfusion; Figure I in the online-only Data Supplement). These 2 models mimic 2 different natural histories of acute ischemic stroke: patients may undergo spontaneous reperfusion of the thrombosed artery because of endogenous thrombolytic mechanisms (tMCAo), or the artery may remain occluded (pMCAo). In the pMCAo model, MPIOs-αVCAM-1-enhanced imaging revealed a sustained VCAM-1 overexpression in the entire brain from +24 hours to +5 days after ischemic onset ( Figure 1A and Figures II and III in the onlineonly Data Supplement), with a cerebrovascular inflammation especially important in the peri-infarct area (yellow arrows in Figure 1A ). Longitudinal studies in the pMCAo model demonstrated that VCAM-1 expression did not change significantly between +24 hours and +5 days in the ipsilateral cortex (from 42.6% at +24 hours to 41.0% at +5 days) but slightly decreased in the contralateral hemisphere (from 13.7% at +24 hours to 9.6% at +5 days; P<0.05). In contrast, in the tMCAo model, VCAM-1 expression was almost exclusively found in the ischemic lesion and gradually decreased over time (signal void volume decreased from 31.2% at +24 hours to 8.4% of the ipsilateral cortex at +5 days; P<0.05; Figure 1A through 1D). These results were replicated in 2 other models of permanent and tMCAo ( Figure IV in the online-only Data Supplement). Overall, these results demonstrate that the cerebrovascular inflammation after pMCAo is strong and sustained, whereas the cerebrovascular inflammation after thrombin-induced tMCAo is mild, restricted to the ischemic lesion, and normalizes rapidly.
MPIOs-αVCAM-1 Predict Delayed Postischemic Injury After MCAo
Thereafter, we investigated whether the inflammatory areas revealed by MPIOs-αVCAM-1-enhanced imaging represent at-risk tissues, which are susceptible to be recruited by the lesion core in the subacute phase. To this aim, we performed MPIOs-αVCAM-1-enhanced imaging at +24 hours and followed the evolution of the stroke-induced lesion by longitudinal T2-weighted imaging. As previously described, 11 the ischemic lesion size significantly increased in the subacute stage after pMCAo (+22.7% between +24 hours and +72 hours; P<0.05; Figure 2A ). According to the results in Figure 1 , at +24 hours, MPIOs-αVCAM-1 enhanced imaging revealed an especially strong VCAM-1 overexpression in spatially restricted areas located around the initial ischemic lesion (yellow arrows on Figure 2A ). Interestingly, a significant part of these highly VCAM-1-expressing areas were subsequently recruited by the ischemic core between +24 hours and +72 hours after pMCAo ( Figure 2B and 2C) . Consistently, similar findings were obtained in another model of permanent ischemia ( Figure IV in the online-only Data Supplement). Immunohistological studies performed +24 hours after pMCAo confirmed the presence of numerous VCAM-1-positive vessels with bound MPIOs-αVCAM-1 at the periphery of the ischemic lesion in MAP-2-positive areas ( Figure 2D ). Moreover, at +72 hours after pMCAo, numerous activated microglial cells were located in the periphery of the lesion, suggesting that panrechymal inflammatory processes occur in this area (Figure V in the online-only Data Supplement). Altogether, these results suggest that the perilesional parenchyma expressing VCAM-1 represent an inflammatory penumbra, which is susceptible to recruitment by the ischemic core in a delayed fashion. The mean fraction of the inflammatory penumbra, which was recruited by the lesion core between +24 hours and +72 hours, was 71% in the electrocoagulation model. However, we cannot exclude a more delayed recruitment of the remaining areas because the extensive lesion remodeling occurring at +5 days precludes accurate localization of the inflammatory penumbra. Importantly, in areas devoid of VCAM-1 overexpression (green dotted line in Figure 2C ), no lesion growth was detected. triggering upregulation of cell adhesion molecules. To further investigate the respective contributions of damageassociated molecular patterns and ischemia/oligemia on cerebrovascular inflammation, we compared VCAM-1 upregulation in 2 experimental paradigms: in the first one, we induced oligemia without brain damage (common carotid artery ligation model). In the second, we induced brain damage without ischemia/oligemia (N-Metyl-D-Aspartate injection model). Interestingly, VCAM-1 upregulation 24 hours after surgery was more important in the common carotid artery ligation model ( Figure VI in the online-only Data Supplement). This result suggests that after ischemic stroke, which involves both ischemia/oligemia and brain damage, cell-death-independent effects of ischemia/ oligemia are mainly responsible for VCAM-1 upregulation. Therefore, the differential pattern of VCAM-1 upregulation in transient and permanent ischemia may be explained by a longer and more severe period of ischemia.
Ischemia
MPIOs-αVCAM-1 Reveal the Anti-Inflammatory Effects of Atorvastatin After Ischemic Stroke
Thereafter, we investigated whether MPIOs-αVCAM-1 could be used to assess the effects of anti-inflammatory drugs on poststroke VCAM-1 expression. We chose celecoxib, atorvastatin, and dipyridamole as 3 potential anti-inflammatory treatments because previous studies had demonstrated their vasoprotective effects. [12] [13] [14] Thus, mice received either 5 mg/kg of celecoxib (intraperitoneal or an equivalent volume of 50% dimethyl sulfoxide in saline), 80 mg/kg of atorvastatin per os (or an equivalent volume of water), 100 mg/kg of dipyridamole (intraperitoneal or an equivalent volume of 5% dimethyl sulfoxide in saline) at +6 hours, +24 hours, and +48 hours after pMCAo. As hypothesized,
MPIOs-αVCAM-1-enhanced imaging revealed a lower level of VCAM-1 expression in celecoxib and atorvastatin-treated mice than in control mice +24 hours after pMCAo ( Figure 3A through 3D ). This reduction was evident in the contralateral cortex but did not reach statistical significance in the ischemic cortex. Interestingly, although the ischemic lesion size at +24 hours did not differ significantly (data not shown), the celecoxib-and atorvastatin-treated mice displayed smaller lesion growth between +24 hours and +72 hours than the corresponding control mice, supporting a role for cerebrovascular inflammation in the delayed expansion of the lesion ( Figure 3B ). Additional immunohistological studies were performed at +24 hours in atorvastatin-treated mice and 
Influence of Tissue-Type Plasminogen ActivatorInduced Thrombolysis on Cerebrovascular Inflammation
Thrombolysis remains the only available treatment for the acute phase of ischemic stroke. We investigated whether tissue-type plasminogen activator-induced thrombolysis 20 minutes after MCAo influences poststroke inflammation in the thrombin model. First, we confirmed that tissuetype plasminogen activator induces early recanalization of the MCA and reduced ischemic lesion size ( Figure I and VIII in the online-only Data Supplement), as previously demonstrated. 15 However, early tissue-type plasminogen activator administration did not significantly influence poststroke cerebrovascular inflammation as assessed by MPIOs-αVCAM-1 enhanced imaging. The effect of late thrombolysis 16 on cerebrovascular inflammation deserves further investigation.
MPIOs-αVCAM-1 Reveal Peri-Hematoma Inflammation in a Model of Intracranial Hemorrhages
In the second part of this study, we investigated whether MPIOs-αVCAM-1-enhanced imaging could detect cerebrovascular inflammation after hemorrhagic stroke. To this aim, we performed longitudinal MPIOs-αVCAM-1-enhanced imaging of mice at +24 hours, +72 hours, and +5 days after collagenase-induced intracranial hemorrhages or intrastriatal saline injection ( Figure 5A ). After MPIOs-αVCAM-1 injection, T2*-weighted imaging revealed numerous signal voids corresponding to VCAM-1-expressing brain vessels in both ipsilateral and contralateral hemispheres at +24 hours ( Figure 5B ). There were significantly more MPIOs-αVCAM-1-induced signal voids in collagenase-treated than in saline-treated mice at +24 hours and at +72 hours ( Figure 5B and Figure IX in the online-only Data Supplement). Five days after hemorrhage induction, the volume of MPIOs-αVCAM-1-induced signal voids almost returned to baseline, but was still significantly higher than in saline-treated mice ( Figure 5C ). In mice injected with control MPIOs-αIgG, no signal void was present, apart from the hematoma itself ( Figure 5B ). On immunohistological examination at +72 hours, numerous Iba-1-positive cells (microglia/macrophages) were detected inside the hematoma (especially at the inner periphery; orange arrows on Figure 5D ), whereas glial fibrillary acidic protein-positive cells (reactive astrocytes, yellow arrowheads) were concentrated at the outer periphery of the hemorrhage. VCAM-1 immunostaining confirmed the MRI findings by revealing numerous VCAM-1 expressing vessels outside the hematoma ( Figure 5D ). Altogether, these data demonstrate the efficiency of molecular MRI of VCAM-1 to evaluate cerebrovascular inflammation after hemorrhagic stroke.
MPIOs-αVCAM-1 Reveal the Anti-Inflammatory Effects of Atorvastatin After Hemorrhagic Stroke
Subsequently, we investigated whether MPIOs-αVCAM-1 could reveal the anti-inflammatory effects of acute atorvastatin treatment on cerebrovascular VCAM-1 expression after intracranial hemorrhage. To this aim, we administered 80 mg/kg of atorvastatin PO at +6 hours, +24 hours, and +48 hours after induction of intracranial hemorrhage. Thereafter, we performed molecular imaging of VCAM-1 at +24 hours and +72 hours. Interestingly, atorvastatin treatment alleviated VCAM-1 overexpression, an effect statistically significant at +72 hours ( Figure 6A through 6C) . Whereas the mean signal void volume was 14.3% and 13.5% of the brain in Figure 3 . Microparticles of iron oxide targeted to vascular cell adhesion molecule-1 (MPIOs-αVCAM-1) reveal the anti-inflammatory effects of celecoxib and atorvastatin after permanent middle cerebral artery occlusion (pMCAo). A, Left: Representative images of longitudinal T2-weighted imaging in control mice revealing delayed postischemic infarction between +24 h and +72 h, which was not present in celecoxib-or atorvastatin-treated mice. Right: Representative image of MPIOs-αVCAM-1-enhanced imaging at +24 h in control mice revealing numerous signal voids in both ipsilateral and contralateral sides, whereas signal voids were almost restricted to the ischemic lesion in celecoxib-or atorvastatin-treated mice. B, Quantification of the lesion size evolution between +24 h and +72 h in control and atorvastatin-treated mice expressed in percentage of the 24-hour lesion size (n=5-6 per group). C, Quantification of the MPIOs-αVCAM-1-induced signal void in the ipsilateral cortex of control, celecoxib-, and atorvastatin-treated mice (n=5-6 per group). D, As in C, but for the contralateral cortex. ns indicates not significant. 
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July 2013 control mice at +24 hours and +72 hours, respectively, it was 10.9% and 5.15% in atorvastatin-treated mice ( Figure 6C ). These results confirm that atorvastatin treatment displays anti-inflammatory effects after hemorrhagic stroke in mice. Moreover, they demonstrate the efficiency of MPIOs-αVCAM-1 in evaluation of the efficacy of anti-inflammatory treatments after intracranial hemorrhage.
Discussion
In the present study, we report for the first time, to our knowledge, a molecular MRI method allowing rapid, sensitive, reliable, and longitudinal assessment of cerebrovascular inflammation after stroke. We demonstrated that MPIOs-αVCAM-1-enhanced imaging provides unique informations about the severity of the cerebrovascular inflammatory response occurring after stroke. Our results suggest that this information may help to improve our current management of stroke patients. Using MPIOs-αVCAM-1-enhanced imaging, we showed that VCAM-1 expression after cerebrovascular events varies spatially and temporally, depending on the ischemic stroke subtype. Whereas in transient ischemic stroke, cerebrovascular inflammation almost completely regressed 5 days after stroke onset, VCAM-1 overexpression was sustained and particularly significant in the peri-infarct area in the permanent model. These results are supported by a recent study demonstrating sustained inflammatory markers after permanent ischemia. 6 We also show that VCAM-1-positive peri-infarct areas were recruited by the ischemic core in the subacute phase, suggesting the existence of an inflammatory penumbra. Although we did not demonstrate a causal relationship between overexpression of VCAM-1 in the peri-infarcted area and the extension of the ischemic lesion, this relationship is supported by a previous study by Liesz et al, 11 who demonstrated that the delayed lesion growth after pMCAo is because of a VCAM-1-dependent blood-brain barrier diapedesis of T-lymphocytes, which exert neurotoxic effects once in the brain parenchyma. More recently, Huang et al also demonstrated that an anti-inflammatory drug (C-X-C chemokine receptor type 4 antagonist) inhibited delayed lesion growth (24 to 72 hours) in another permanent ischemia model. 17 Interestingly, the particular kinetics of this delayed infarction suggests that patients presenting an inflammatory penumbra at 24 hours may still benefit from therapy targeting the interaction between leucocytes and the vascular wall (such as the multiple-sclerosis drug Natalizumab).
11
In the subacute stage of ischemic stroke, we demonstrated that celecoxib and atorvastatin alleviate cerebrovascular inflammation and prevent formation of the inflammatory penumbra. Because statins are safely administered as VCAM-1) expression after permanent ischemic stroke. A, Left: Representative immunohistological images in control and atorvastatin-treated mice revealing VCAM-1+ vessels in the ischemic core at +24 h after permanent middle cerebral artery occlusion (pMCAo; arrows). Right: Corresponding quantification of VCAM-1+ vessels (n=5 per group). Extravascular VCAM-1 immunoreactivity coming from dead (or dying) cells was not considered. B, As in A, but the images were taken and the quantification was done in the periphery of the lesion, defined as the area distant from <500 μm from the limit between ischemic and nonischemic tissues. C, As in B, but the images were taken and the quantification was done in the contralateral (nonischemic) side. D, High-magnification immunohistological images revealing numerous microparticles of iron oxides (MPIOs)-αVCAM-1 (white dots on the dark field image) in a VCAM-1+ vessel. The yellow dotted line delineates the ischemic lesion. CollV indicates Callogen type IV; DAPI, 4',6-diamidino-2-phenylindole; and MAP-2, microtubuleassociated protein-2. prophylactic drugs in poststroke patients (at much smaller doses), our results support the fact that ischemic stroke patients could benefit from statin administration in the early phase to limit potential delayed inflammatory damages. 18 It is interesting to note that a recent meta-analysis of statin efficiency in experimental models of ischemic stroke indicates that statin therapy may be more efficient in permanent than in transient models. 19 Our results using MPIOs-αVCAM-1-enhanced imaging suggest that this discrepancy could be explained by the more sustained inflammatory response occurring after pMCAo than after tMCAo. Because the effect of statins is pleiotropic, whether the observed preventive effects on delayed lesion growth are solely caused by the downregulation of VCAM-1 deserves further investigation. Altogether, these data emphasize the interest of molecular imaging to select subgroups of patients who may benefit from anti-inflammatory therapy, thereby improving the benefit/risk profile of the treatment.
We also demonstrated that MPIOs-αVCAM-1 allow noninvasive assessment of cerebrovascular inflammation after collagenase-induced intracranial hemorrhage. Because high concentration of soluble VCAM-1 in the cerebrospinal fluid is associated with poor outcome in patients with hemorrhagic stroke, 20 it has been suggested that particular subsets of patients presenting strong overexpression of VCAM-1 could benefit from anti-inflammatory treatment. MPIOs-αVCAM-1-enhanced imaging could be useful in identifying these patients to test innovative anti-inflammatory strategies. One such strategy could be the administration of statins, which showed potential therapeutic efficiency in patients with subarachnoid hemorrhages. 21 Indeed, we demonstrated here that statin administration significantly alleviates the cerebrovascular 
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inflammation after intracranial hemorrhage. These results confirm previous experimental studies and support further development of this therapeutic strategy for clinical use.
22
A potential limit of MPIOs-based imaging (common to all negative contrast agents) is the occurrence of false-positive findings because of disease-related T2* effects (such as hemorrhages; Figure 5 ), which should be carefully identified on precontrast images. Moreover, the currently used MPIOs in experimental studies are not biodegradable and cannot be used in clinical studies. Therefore, clinical translation of this method would require production of biocompatible MPIOs. Whether MPIOs-αVCAM-1 could interfere with the binding of leucocytes to the vascular wall also deserves further investigations.
In conclusion, we demonstrate here that MPIOs-αVCAM-1-enhanced imaging allows evaluation of the poststroke cerebrovascular inflammation in a timely and highly sensitive manner. Notably, the cerebrovascular inflammation is particularly severe in the intact areas surrounding the ischemic lesion after pMCAo, suggesting the presence of an inflammatory penumbra that is recruited by the lesion core in the subacute phase. Altogether, our results suggest that the presence of an inflammatory penumbra after ischemic stroke could constitute an imaging criterion to select patients for subacute antiinflammatory treatments.
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